Developing novel product candidates for cancer & respiratory viral diseases
A clinical stage company aiming to address unmet medical needs in cancer and respiratory viral diseases
Traws Pharma leverages broad and deep expertise in small molecule chemistry, artificial intelligence and machine learning, rational drug design & streamlined development to deliver innovative medicines. We target critical threats to human health, aiming to overcome problems caused by acquired resistance to current medications, with an additional focus on vulnerable populations
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced financial results for the first quarter of 2024, and provided a business update.
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Traws Pharma, Inc. (“Traws” or “Traws Pharma”) today announced that it completed dosing in the first cohort of the first-in-human Phase 1 study to evaluate travatrelvir (TRX01), an orally-available protease inhibitor, in development for treatment of COVID19.